These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 36657725)
21. A Cell-Permeant Mimetic of NMN Activates SARM1 to Produce Cyclic ADP-Ribose and Induce Non-apoptotic Cell Death. Zhao ZY; Xie XJ; Li WH; Liu J; Chen Z; Zhang B; Li T; Li SL; Lu JG; Zhang L; Zhang LH; Xu Z; Lee HC; Zhao YJ iScience; 2019 May; 15():452-466. PubMed ID: 31128467 [TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Yi L; Maier AB; Tao R; Lin Z; Vaidya A; Pendse S; Thasma S; Andhalkar N; Avhad G; Kumbhar V Geroscience; 2023 Feb; 45(1):29-43. PubMed ID: 36482258 [TBL] [Abstract][Full Text] [Related]
23. Axon Death Pathways Converge on Axundead to Promote Functional and Structural Axon Disassembly. Neukomm LJ; Burdett TC; Seeds AM; Hampel S; Coutinho-Budd JC; Farley JE; Wong J; Karadeniz YB; Osterloh JM; Sheehan AE; Freeman MR Neuron; 2017 Jul; 95(1):78-91.e5. PubMed ID: 28683272 [TBL] [Abstract][Full Text] [Related]
24. cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons. Sasaki Y; Engber TM; Hughes RO; Figley MD; Wu T; Bosanac T; Devraj R; Milbrandt J; Krauss R; DiAntonio A Exp Neurol; 2020 Jul; 329():113252. PubMed ID: 32087251 [TBL] [Abstract][Full Text] [Related]
25. NAD and axon degeneration: from the Wlds gene to neurochemistry. Wang J; He Z Cell Adh Migr; 2009; 3(1):77-87. PubMed ID: 19372760 [TBL] [Abstract][Full Text] [Related]
26. An NAD+/NMN balancing act by SARM1 and NMNAT2 controls axonal degeneration. Waller TJ; Collins CA Neuron; 2021 Apr; 109(7):1067-1069. PubMed ID: 33831359 [TBL] [Abstract][Full Text] [Related]
27. A Novel NAD Signaling Mechanism in Axon Degeneration and its Relationship to Innate Immunity. Hopkins EL; Gu W; Kobe B; Coleman MP Front Mol Biosci; 2021; 8():703532. PubMed ID: 34307460 [TBL] [Abstract][Full Text] [Related]
28. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Song Q; Zhou X; Xu K; Liu S; Zhu X; Yang J Adv Nutr; 2023 Nov; 14(6):1416-1435. PubMed ID: 37619764 [TBL] [Abstract][Full Text] [Related]
29. SARM1 is required in human derived sensory neurons for injury-induced and neurotoxic axon degeneration. Chen YH; Sasaki Y; DiAntonio A; Milbrandt J Exp Neurol; 2021 May; 339():113636. PubMed ID: 33548217 [TBL] [Abstract][Full Text] [Related]
34. SARM1 is a multi-functional NAD(P)ase with prominent base exchange activity, all regulated bymultiple physiologically relevant NAD metabolites. Angeletti C; Amici A; Gilley J; Loreto A; Trapanotto AG; Antoniou C; Merlini E; Coleman MP; Orsomando G iScience; 2022 Feb; 25(2):103812. PubMed ID: 35198877 [TBL] [Abstract][Full Text] [Related]
35. NAD Cao Y; Wang Y; Yang J Cell Insight; 2022 Apr; 1(2):100019. PubMed ID: 37193131 [TBL] [Abstract][Full Text] [Related]
36. Nicotinamide mononucleotide protects against β-amyloid oligomer-induced cognitive impairment and neuronal death. Wang X; Hu X; Yang Y; Takata T; Sakurai T Brain Res; 2016 Jul; 1643():1-9. PubMed ID: 27130898 [TBL] [Abstract][Full Text] [Related]
37. SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation. Summers DW; Gibson DA; DiAntonio A; Milbrandt J Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6271-E6280. PubMed ID: 27671644 [TBL] [Abstract][Full Text] [Related]
38. The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions. Soma M; Lalam SK Mol Biol Rep; 2022 Oct; 49(10):9737-9748. PubMed ID: 35441939 [TBL] [Abstract][Full Text] [Related]
39. Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules. Shi Y; Kerry PS; Nanson JD; Bosanac T; Sasaki Y; Krauss R; Saikot FK; Adams SE; Mosaiab T; Masic V; Mao X; Rose F; Vasquez E; Furrer M; Cunnea K; Brearley A; Gu W; Luo Z; Brillault L; Landsberg MJ; DiAntonio A; Kobe B; Milbrandt J; Hughes RO; Ve T Mol Cell; 2022 May; 82(9):1643-1659.e10. PubMed ID: 35334231 [TBL] [Abstract][Full Text] [Related]
40. Improvement of tissue-specific distribution and biotransformation potential of nicotinamide mononucleotide in combination with ginsenosides or resveratrol. Bai LB; Yau LF; Tong TT; Chan WH; Zhang W; Jiang ZH Pharmacol Res Perspect; 2022 Aug; 10(4):e00986. PubMed ID: 35844164 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]